<DOC>
	<DOC>NCT00408967</DOC>
	<brief_summary>The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression</brief_summary>
	<brief_title>Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Signed written informed consent Age 18 years or older Have histologically documented ovarian carcinoma (including primary peritoneal carcinoma) Have archival tumor tissue available for EpCAM expression determination by immunohistochemistry Received firstline platinumbased chemotherapy of up to 8 cycles (approximately 15 to 24 weeks) Experienced a complete response to firstline platinumbased chemotherapy Experienced a platinumfree interval of at least 6 but not more than 24 months starting at the end of the last cycle of firstline chemotherapy until recurrence Treatment with Avastin (bevacizumab) is permitted during firstline platinumbased chemotherapy through TTP and platinumbased reinduction therapy up to 28 days prior to start of EMD 273066 Experienced a partial or complete response after up to 8 cycles of secondline platinumbased chemotherapy Have a CT/MRI scan within 4 weeks prior to starting treatment Be able to start cyclophosphamide and EMD 273066 treatment within 3 to 5 weeks of completion of secondline chemotherapy KPS ≥70% No clinical history of significantly impaired renal function or chronic kidney disease. Must have an estimated glomerular filtration rate ≥50 mL/min determined by the CockgroftGaultformula WBC count ≥2.5x10³/µL (or total granulocytes ≥1x10³/µL) Absolute lymphocyte count (ALC) ≥0.5x103/µL Platelet count ≥100,000/µL Hemoglobin (Hgb) level ≥9 g/dl ALT and AST ≤2.5xULN, total bilirubin &lt;1.5xULN Serum sodium, potassium and phosphorus within normal limits Serum amylase within normal limits Serologic testing within 4 weeks prior to starting study treatment with negative results for hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV) demonstrated by negative hepatitis B core antibody (HBc Ab) and hepatitis B surface antigen (HbsAg) Negative pregnancy test and willingness to use effective contraception for the study duration and 1 month thereafter if of procreative potential Dyspnea at rest, exercise intolerance In any subject with clinically significant nonmalignant pulmonary disease: Pulmonary function testing (to include Forced Vital Capacity [FVC] and 1second Forced Expiratory Volume [FEV1]) showing &lt;70% of predicted values for FVC or FEV1 and/or DLCO &lt;50%. In any subject with pulmonary or pleural metastatic disease: Arterial oxygen saturation at rest measured transcutaneously on room air &lt; 90% or increased risk for respiratory compromise related to IL2 exposure in the judgment of the investigator. ECG with evidence of clinically significant disease within 4 weeks prior to starting study treatment Cardiac stress test (e.g., exercise or pharmacological thallium test; exercise or pharmacological echocardiography) with abnormal results within 4 weeks prior to starting treatment in subjects who have a history of coronary heart disease (myocardial infarction, angina pectoris or pathologic coronary angiography) Any current evidence of congestive heart failure with NY Heart Association Grade 2 through 4 or echocardiogram with a left ventricular ejection fraction &lt;45% or other signs of clinical significant heart disease History of repeated and clinically relevant episodes of syncope or other paroxysmal, ventricular, or other clinically significant arrhythmias Evidence of active brain metastases Previous malignancy other than ovarian cancer in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix Pregnant or lactating female An immediate need for palliative radiotherapy or systemic corticosteroid therapy Significant active infection Major surgery, chemotherapy, or radiation within 21 days of starting study treatment Received another experimental drug within 28 days of starting study treatment Uncontrolled hypertension (systolic ≥180 mmHg or diastolic ≥100 mmHg) or hypotension (systolic ≤90 mmHg) Presence of medically significant third space fluids such as pleural or pericardial effusions or edema of toxicity grade ≥2 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 [17]. Exception allowed for diseaserelated peritoneal ascites unless patient requires frequent and repetitive paracentesis management. Previous diagnosis of an autoimmune disease involving a major organ system Transplant recipient on immunosuppressive therapy Acute esophageal or gastroduodenal ulcers History of prior therapy or a serious uncontrolled medical disorder that in the Investigator's opinion would impair participation in the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Cancer</keyword>
	<keyword>Epithelial</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Platinum</keyword>
	<keyword>Second-line therapy</keyword>
	<keyword>Maintenance Therapy</keyword>
	<keyword>Biologic</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Antibody</keyword>
</DOC>